Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy‐resistant advanced renal cell carcinoma
Camillo Porta(University of Pavia), Alberto Riccardi(Istituti di Ricovero e Cura a Carattere Scientifico), Matteo Zimatore, Ilaria Imarisio(University of Pavia), Marco Danova(Azienda Socio Sanitaria Territoriale di Pavia), Andrea Sartore‐Bianchi(University of Milan), Anna Natalizi(Istituti di Ricovero e Cura a Carattere Scientifico)
Cited by 23
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821